Oct 18, 16:10
7608.15 74.70 (0.99%)
| Intraday | 52 Week | |
|---|---|---|
| OPEN: 7,530.65 | HIGH: 7,651.95 | 9,925.05 |
| PREV CLOSE: 7,533.45 | LOW: 7,500.50 | 7,047.10 |
| YTD | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 2 Year | 3 Year |
| -14.21% | 4.10% | -5.00% | -9.60% | -19.90% | -22.20% | -22.70% | -33.20% |
Stock
| Month | Oct'19 | Sep'19 | Aug'19 | Jul'19 | Jun'19 | May'19 |
|---|---|---|---|---|---|---|
| HIGH | 7651.95 | 8168.50 | 8112.55 | 8363.75 | 8602.05 | 9419.70 |
| LOW | 7047.10 | 7509.10 | 7550.55 | 7791.10 | 7737.00 | 8244.65 |
| CLOSE | 7608.15 | 7547.75 | 8072.05 | 7987.50 | 8065.15 | 8455.10 |
| NAME | SECTOR | LAST PRICE | MKT. CAP. |
|---|---|---|---|
| Aurobindo Pharm | Pharmaceuticals | 476.45 | 27,917.05 |
| Cadila Health | Pharmaceuticals | 240.65 | 24,636.37 |
| Cipla | Pharmaceuticals | 444.15 | 35,801.93 |
| Divis Labs | Pharmaceuticals | 1,738.00 | 46,138.44 |
| Dr Reddys Labs | Pharmaceuticals | 2,724.85 | 45,272.22 |
| POSITIVE CONTRIBUTIONS | |
|---|---|
| Company | Points |
| Piramal Enter | 35.21 |
| Aurobindo Pharm | 11.79 |
| Lupin | 11.47 |
| Divis Labs | 8.04 |
| Glenmark | 6.42 |
| NEGATIVE CONTRIBUTIONS | |
|---|---|
| Company | Points |
| Cipla | -3.49 |
| Dr Reddys Labs | -0.85 |
| GlaxoSmithKline | -0.48 |
| Add a comment...
as told before for investing avoid IT PHARMA and all dollar dependent stocks thats the assessment as per the charts , news and fundamentals will follow one by one today INFY , tomm something else, despite of this nifty will continue to go u...  See more
Posted by : beginnertrader
They have already started, cut in corporate tax was fst step, next will be reform in income tax and removal of LTCG.They have taken some serious steps in there PSU disinvestment, So this bold step will create a huge upside in Mkt,.Since Jan...  See more | 3
Posted by : ambrishtiwari675
Copyright © e-Eighteen.com Ltd All rights resderved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express writtern permission of moneycontrol.com is prohibited.
Market Commentary